New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 14, 2014
08:32 EDTLGND, AZNLigand signs research and licensing agreement with Omthera Pharmaceuticals
Ligand Pharmaceuticals (LGND) announced that it has entered into a licensing agreement and research collaboration with Omthera Pharmaceuticals, a wholly-owned subsidiary of AstraZeneca (AZN), for the development of products to treat dyslipidemia, including hypertriglyceridemia. The research collaboration will target the development of novel products that utilize the proprietary Ligand-developed LTP TECHNOLOGY to improve lipid-lowering activity of certain omega-3 fatty acids. Under the terms of the agreement, Ligand will be eligible to receive payments of up to $44.5M upon the achievement of specific milestones, as well as tiered royalties ranging from mid to high single digits of net sales. Omthera is solely responsible for all research and clinical development costs as well as commercialization of any product(s) derived from this collaboration.
News For LGND;AZN From The Last 14 Days
Check below for free stories on LGND;AZN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2014
05:25 EDTAZNAdams Express, MedImmune announce clinical trial partnership
Advaxis (ADXS) has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca (AZN). The Phase I/II immunotherapy study will evaluate the safety and efficacy of MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis' lead cancer immunotherapy vaccine, ADXS-HPV, as a treatment for patients with advanced, recurrent or refractory human papillomavirus, or HPV,-associated cervical cancer and HPV-associated head and neck cancer. Both MEDI4736 and ADXS-HPV are cancer immunotherapies, a new class of treatments that use the body's own immune system to help fight cancer. Under the terms of the agreement, MedImmune and Advaxis will evaluate the combination as a treatment for HPV-associated cervical cancer and squamous cell carcinoma of the head and neck. The Phase I part of the trial is expected to establish a recommended dose regimen of MEDI4736 with ADXS-HPV, and the Phase II portion will assess the safety and efficacy of the combination. The study will be funded and conducted by Advaxis. Results from the study will be used to determine whether further clinical development of this combination is warranted. Under the terms of the deal, MedImmune has a non-exclusive relationship with respect to HPV-driven tumour types. MedImmune has first right of negotiation for future development of combinations involving MEDI4736 and ADXS-HPV.
July 17, 2014
08:02 EDTLGNDLigand sees Q2 revenue $10.6M, above previous guidance of $9M-$9.5M
Subscribe for More Information
08:01 EDTLGNDLigand board authorizes $10M repurchase program
Subscribe for More Information
July 16, 2014
10:36 EDTAZNTreasury calls on Congress to halt inversion deals
Subscribe for More Information
09:41 EDTLGNDLigand management to meet with Roth Capital
Subscribe for More Information
08:01 EDTAZNAlexion names former AstraZeneca CEO David Brennan to board
Subscribe for More Information
07:59 EDTAZNTreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
July 14, 2014
07:20 EDTLGNDControlled Released Society to hold annual meeting
Subscribe for More Information
July 8, 2014
07:17 EDTAZNLeerink raises immuno-oncology market forecast to $36B
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use